SAN FRANCISCO, Jan. 12, 2017 -- Hagens Berman Sobol Shapiro LLP alerts investors in Novo Nordisk A/S (NYSE:NVO) to the securities class action lawsuit filed in the U.S. District Court for the District of New Jersey and to the March 13, 2017 Lead Plaintiff deadline.
If you purchased or otherwise acquired NVO between April 30, 2015 and October 27, 2016 and suffered over $200,000 in losses contact Hagens Berman Sobol Shapiro LLP. For more information visit:
https://www.hbsslaw.com/cases/NVO
or contact Reed Kathrein, who is leading the firm’s investigation, by calling 510-725-3000 or emailing [email protected].
After repeatedly assuring investors of sales and profit growth, NVO announced its second consecutive quarter of disappointing earnings and slashed long-term profit-growth forecasts by 50% on October 28, 2016. In addition, NVO revealed it was being investigated by the U.S. Attorney’s Office for potentially improper arrangements with pharmacy benefits managers who purchase NVO’s insulin products. This news drove the price of the Company’s ADRs down approximately 13%.
“We’re focused on NVO’s insulin--and other--pricing matters and Defendants’ growth-related statements,” said Hagens Berman partner Reed Kathrein.
Whistleblowers: Persons with non-public information regarding NVO should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new SEC whistleblower program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 510-725-3000 or email [email protected].
About Hagens Berman
Hagens Berman is a national investor-rights law firm headquartered in Seattle, Washington with offices in 10 cities. The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the Firm and its successes can be found at www.hbsslaw.com. Read the Firm’s Securities Newsletter, and visit the blog. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.
Contact: Reed Kathrein, 510-725-3000


Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding?
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs
Apple Turns 50: From Garage Startup to AI Crossroads
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown
Luxury Car Sales in the Middle East Take a Hit Amid Iran War
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 



